Insurance Coverage Lags as Cancer Science, Treatment Move Forward

Mason Henderson with his mother, Tabitha Lowe, in November during a visit to New York, where Henderson was participating in a clinical trial to treat his brain cancer. Henderson died in May after a two-year battle with the disease. (Jerry Lowe) Eighteen months after his initial diagnosis, chemotherapy hadn’t slowed 21-year-old Mason Henderson’s rare brain…

Read More

AI: To Regulate, or Not to Regulate?

Across the tech industry, many of AI’s own leaders are calling for oversight — self-imposed or from government. That debate is on, but where it will land is anyone’s guess. Joe Grogan takes a different tack: the biggest threat in health care AI may not be too little regulation, but the wrong kind.

Read More

Radiopharmaceutical Dealmaking Continues With Telix’s $1.65B ITM Acquisition

Telix Pharmaceuticals is acquiring Isotope Technologies Munich, or ITM, in a $1.65 billion stock deal that will create a radiopharmaceuticals company with greater global scale. ITM’s lead pipeline asset is in late-stage development for a type of gastrointestinal cancer, where it could compete against Novartis and Curium Pharma products. The post Radiopharmaceutical Dealmaking Continues With…

Read More